Skip to Content

UK Edition. Click here for US version.

CONTIFLO XL 400 MICROGRAMS CAPSULES

Active substance(s): TAMSULOSIN HYDROCHLORIDE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Contiflo XL 400 micrograms capsules

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged release capsule contains as active ingredient 400 micrograms of
tamsulosin hydrochloride.
Excipients with known effect:
One prolonged release capsule contains 0.0353 mg of sunset yellow, 0.0013 mg of
Ponceau 4R, 0.0008 mg of brilliant blue and 0.0019 mg of azorubine
For the full list of excipients, see section 6.1.

3

PHARMACEUTICAL FORM
Prolonged release capsule
Brown /Orange size “2”capsules imprinted with ‘R’ on cap and ´TSN400’ on body in
black. The capsules contain white to off-white granules.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia
(BPH).

4.2

Posology and method of administration
Posology
Oral use.
One capsule daily, to be taken after breakfast or the first meal of the day.

The capsule must be swallowed whole and should not be crunched or chewed as this
interferes with the modified release of the active ingredient.
No dose adjustment is warranted in renal impairment. No dose adjustment is
warranted in patients with mild to moderate hepatic insufficiency (see also 4.3
Contraindications).
Paediatric population
There is no relevant indication for use of this medicine product in children.
The safety and efficacy of tamsulosin in children < 18 years have not been
established. Currently available data are described in section 5.1.

4.3

Contraindications
Hypersensitivity to the active substance, including drug-induced angioedema, or to
any of the excipients listed in section 6.1.
A history of orthostatic hypotension.
Severe hepatic insufficiency.

4.4

Special warnings and precautions for use
As with other α 1-adrenoceptors antagonists, a reduction in blood pressure can occur
in individual cases during treatment with tamsulosin, as a result of which, rarely,
syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness),
the patient should sit or lie down until the symptoms have disappeared.
Before therapy with tamsulosin is initiated, the patient should be examined in order to
exclude the presence of other conditions, which can cause the same symptoms as
benign prostatic hyperplasia. Digital rectal examination and, when necessary,
determination of prostate specific antigen (PSA) should be performed before
treatment and at regular intervals afterwards.
The treatment of patients with severe renal impairment (creatinine clearance of < 10
ml/min) should be approached with caution, as these patients have not been studied.
The ‘Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome)
has been observed during cataract surgery in some patients on or previously treated
with tamsulosin hydrochloride. IFIS may increase the risk of eye complications
during and after the operation.
Discontinuing tamsulosin hydrochloride 1-2 weeks prior to cataract surgery is
anecdotally considered helpful, but the benefit of treatment discontinuation has not
yet been established. IFIS has also been reported in patients who had discontinued
tamsulosin for a longer period prior to cataract surgery. The initiation of therapy with
tamsulosin hydrochloride in patients for whom cataract surgery is scheduled is not
recommended.

During pre-operative assessment, cataract surgeons and ophthalmic teams should
consider whether patients scheduled for cataract surgery are being or have been
treated with tamsulosin in order to ensure that appropriate measures will be in place
to manage the IFIS during surgery.
Tamsulosin hydrochloride should not be given in combination with strong inhibitors
of CYP3A4 in patients with poor metaboliser CYP2D6 phenotype.
Tamsulosin hydrochloride should be used with caution in combination with strong
and moderate inhibitors of CYP3A4 (see section 4.5).
Allergic reactions to the presence of colouring agents azorubine (E122), ponceau 4R
(E124) and sunset yellow (E110) may occur.

4.5

Interaction with other medicinal products and other forms of interaction
Interaction studies have only been performed in adults
No interactions have been seen when tamsulosin hydrochloride was given
concomitantly with either atenolol, enalapril or theophylline.
Concomitant cimetidine brings about a rise in plasma levels of tamsulosin,
whereasfurosemide a fall, but as levels remain within the normal range, posology
need not be adjusted.
In vitro, neither diazepam nor propranolol, trichlormethiazide, chlormadinon,
amitriptyline, diclofenac, glibenclamide, simvastatin and warfarin change the free
fraction of tamsulosin in human plasma. Neither does tamsulosin change the free
fractions of diazepam, propranolol, trichlormethiazide, and chlormadinon.
Diclofenac and warfarin, however, may increase the elimination rate of tamsulosin.
Concomitant administration of tamsulosin hydrochloride with strong inhibitors of
CYP3A4 may lead to increased exposure to tamsulosin hydrochloride. Concomitant
administration with ketoconazole (a known strong CYP3A4 inhibitor) resulted in an
increase in AUC and Cmax of tamsulosin hydrochloride by a factor of 2.8 and 2.2,
respectively.
Tamsulosin hydrochloride should not be given in combination with strong inhibitors
of CYP3A4 in patients with poor metaboliser CYP2D6 phenotype.
Tamsulosin hydrochloride should be used with caution in combination with strong
and moderate inhibitors of CYP3A4.

Concomitant administration of tamsulosin hydrochloride with paroxetine, a strong
inhibitor of CYP2D6, resulted in a Cmax and AUC of tamsulosin that had increased
by a factor of 1.3 and 1.6, respectively, but these increases are not considered
clinically relevant.
Concurrent administration of other α1-adrenoceptor antagonists could lead to
hypotensive effects.

4.6

Fertility, pregnancy and lactation
Tamsulosin is not indicated for use in women.
Ejaculation disorders have been observed in short and long term clinical studies with
tamsulosin. Events of ejaculation disorder, retrograde ejaculation and ejaculation
failure have been reported in the post authorization phase.

4.7

Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been
performed. However, patients should be aware of the fact that dizziness can occur.

4.8

Undesirable effects

System Organ
Class

Common
> 1/100,
< 1/10

Uncommon
>1/1.000,
< 1/100

Rare
> 1/10.000,
< 1/1.000

Nervous system
disorders

Dizziness
(1.3%)

Headaches

Syncope

Respiratory,
thoracic and
mediastinal
disorders

Not known

Vision
blurred,
visual
impairment

Eye disorders

Cardiac
disorders
Vascular
disorders

Very
rare
<
1/10.000

Palpitations
orthostatic
hypotension
Rhinitis

Epistaxis

Gastrointestinal
disorders

Skin and
subcutaneous
tissue disorders
Reproductive
system and
breast
disorders

General
disorders and
administration
site conditions

Constipation,
diarrhoea,
nausea
vomiting

Dry mouth

rash, pruritus angioedema Stevens- Erythema
Johnson
multiforme,
and urticaria
syndrome Dermatitis
Ejaculation
priapism
disorders
Retrograde
ejaculation,
Ejaculation
failure
Asthenia

During cataract surgery a small pupil situation, known as Intraoperative Floppy Iris
Syndrome (IFIS), has been associated with therapy of tamsulosin during postmarketing surveillance (see also section 4.4).
Post-marketing experience: In addition to the adverse events listed above, atrial
fibrillation, arrhythmia, tachycardia and dyspnoea have been reported in association
with tamsulosin use. Because these spontaneously reported events are from the
worldwide post marketing experience, the frequency of events and the role of
tamsulosin in their causation cannot be reliably determined.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard.
4.9

Overdose
Symptoms
Overdosage with tamsulosin hydrochloride can potentially result in severe
hypotensive effects. Severe hypotensive effects have been observed at different levels
of overdosing.
Treatment
In case of acute hypotension occurring after overdosage cardiovascular support
should be given.
Blood pressure can be restored and heart rate can be brought back to normal by lying
the patient down. If this does not help then volume expanders and, when necessary,
vasopressors could be employed.

Renal function should be monitored and general supportive measures applied.
Dialysis is unlikely to be of help as tamsulosin is very highly bound to plasma
proteins.
Measures, such as emesis, can be taken to impede absorption.
When large quantities are involved, gastric lavage can be applied and activated
charcoal and an osmotic laxative (such as sodium sulphate) can be administered.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Pharmacotherapeutic group: Alpha-adrenoreceptor antagonists.
ATC code: G04C A02.
Preparations for the exclusive treatment of prostatic disease.
Mechanism of action:
Tamsulosin binds selectively and competitively to postsynaptic α1-adrenoceptors, in
particular to the subtypes α1A and α1D. It brings about relaxation of prostatic and
urethral smooth muscle.
Pharmacodynamic effects:
Tamsulosin increases the maximum urinary flow rate. It relieves obstruction by
relaxing the smooth muscle in the prostate and urethra thereby improving voiding
symptoms.
It also improves the storage symptoms in which bladder instability plays an important
role.
These effects on storage and voiding symptoms are maintained during long -term
therapy. The need for surgery or catheterization is significantly delayed.

α1-adrenoceptors antagonists can reduce blood pressure by lowering peripheral
resistance.
No reduction in blood pressure of any clinical significance was observed during
studies with tamsulosin.
Paediatric population
A double-blind, randomized, placebo-controlled, dose ranging study was performed
in children with neuropathic bladder. A total of 161 children (with an age of 2 to 16

years) were randomized and treated at 1 of 3 dose levels of tamsulosin (low [0.001 to
0.002 mg/kg], medium [0.002 to 0.004 mg/kg], and high [0.004 to 0.008 mg/kg]), or
placebo. The primary endpoint was number of patients who decreased their detrusor
leak point pressure (LPP) to <40 cm H2O based upon two evaluations on the same
day. Secondary endpoints were: Actual and percent change from baseline in detrusor
leak point pressure, improvement or stabilization of hydronephrosis and hydroureter
and change in urine volumes obtained by catheterisation and number of times wet at
time of catheterisation as recorded in catheterisation diaries. No statistically
significant difference was found between the placebo group and any of the 3
tamsulosin dose groups for either the primary or any secondary endpoints. No dose
response was observed for any dose level.

5.2

Pharmacokinetic properties

Absorption
Tamsulosin hydrochloride is absorbed from the intestine and is almost completely
bioavailable.
Absorption of tamsulosin hydrochloride is reduced by a recent meal. Uniformity of absorption
can be promoted by the patient always taking Tamsulosin Ranbaxy 0.4 mg Prolonged release
capsules after the same meal.
Tamsulosin shows linear kinetics.
After a single dose of tamsulosin in the fed state, plasma levels of tamsulosin peak at around
6 hours and, in the steady state, which is reached by day 5 of multiple dosing, Cmax in
patients is about two thirds higher than that reached after a single dose.
Although this was seen in the older patients, the same finding would also be expected in
young ones.
There is a considerable inter-patient variation in plasma levels, both after single and multiple
dosing.
Distribution
In man, tamsulosin is about 99% bound to plasma proteins. The volume of distribution is
small (about 0.2 l/kg).
Biotransformation
Tamsulosin has a low first pass effect, being metabolised slowly. Most tamsulosin is present
in plasma in the form of unchanged active substance. It is metabolized in the liver.
In rats, hardly any induction of microsomal liver enzymes was seen to be caused by
tamsulosin.
In vitro results suggest that CYP3A4 and also CYP2D6 are involved in metabolism, with
possible minor contributions to tamsulosin hydrochloride metabolism by other CYP
isozymes. Inhibition of CYP3A4 and CYP2D6 drug metabolizing enzymes may lead to
increased exposure to tamsulosin hydrochloride (see section 4.4 and 4.5).
None of the metabolites are more active than the original compound.
Elimination
Tamsulosin and its metabolites are mainly excreted in the urine with about 9% of a dose being
present in the form of unchanged active substance.

After a single dose of tamsulosin in the fed state, and in the steady state in patients,
elimination half-lives of about 10 and 13 hours, respectively, have been measured.

5.3

Preclinical safety data
Single and repeat dose toxicity were performed in mice, rats and dogs.
In addition, reproduction toxicity studies in rats, carcinogenicity in mice and rats, and
in vivo and in vitro genotoxicity were examined.
The general toxicity profile, as seen with high doses of tamsulosin, is consistent with
the known pharmacological actions of the α1-adrenoceptors antagonists.
At very high dose levels, the ECG was altered in dogs. This response is considered to
be not clinically relevant. Tamsulosin showed no relevant genotoxic properties.
Increased incidence of proliferative changes of mammary glands of female rats and
mice have been reported. These findings, which are probably mediated by
hyperprolactinaemia and only occurred at high dose levels, are regarded as irrelevant.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients

Capsule contents:
Cellulose microcrystalline PH101
Magnesium stearate
Methacrylic acid-ethyl acrylate copolymer (1:1) dispersion
Sodium hydroxide
Triacetin
Titanium dioxide (E171)
Purified talc.
Capsule body:
Gelatine
Sunset yellow
Ponceau 4R (E124)
Quinoline yellow (E104)
Brilliant blue (E133)
Titanium dioxide (E171).
Cap composition:
Gelatine
Yellow iron oxide (E172)

Brilliant blue (E133)
Azorubine (E122)
Titanium dioxide (E171).
Printing ink:
Shellac
Black Iron oxide (E172)
Potassium Hydroxide
6.2

Incompatibilities
Not applicable

6.3

Shelf life
2 years

6.4

Special precautions for storage
This medicinal product does not require any special storage conditions.

6.5

Nature and contents of container

PVC/PVdC/Alu blisters.
Packs of 1, 2, 4, 7, 10, 14, 20, 28, 30, 50, 56, 60, 90, 98, 100 or 200 prolonged release
capsules.
Not all packs sizes may be marketed.
6.6

Special precautions for disposal
No special requirements.

7

MARKETING AUTHORISATION HOLDER

Ranbaxy (UK.) Limited
Building 4 Chiswick Park
London
United Kingdom

W4 5YE

8

MARKETING AUTHORISATION NUMBER(S)
PL 14894/0466

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
04/11/2010

10

DATE OF REVISION OF THE TEXT
20/10/2015

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide